GENFIT Share Price Xetra
Stocks
XUP
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.30 EUR | -0.45% |
|
-2.21% | +149.77% |
| 03/07 | Genfit soars on news of U.S. reimbursement for a product |  |
| 03/07 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 65Cr 74Cr 60Cr 55Cr 103.45Cr 7.11TCr 105.75Cr 711.74Cr 279.95Cr 3.48TCr 277.32Cr 271.23Cr 12TCr | P/E 2026 * |
67.8x | P/E 2027 * | 85.7x |
|---|---|---|---|---|---|
| Enterprise Value | 59Cr 68Cr 55Cr 51Cr 95Cr 6.55TCr 97Cr 655.36Cr 257.77Cr 3.21TCr 255.35Cr 249.75Cr 11TCr | EV / Sales 2026 * |
5.93x | EV / Sales 2027 * | 4.67x |
| Free-Float |
86.88% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -0.45% | ||
| 1 week | -2.21% | ||
| Current month | +52.17% | ||
| 1 month | +52.17% | ||
| 3 months | +44.88% | ||
| 6 months | +141.82% | ||
| Current year | +149.77% |
| 1 week | 13.14 |  | 13.46 |
| 1 month | 13.14 | | 13.6 |
| Current year | 5.2 | | 13.6 |
| 1 year | 3.19 | | 13.6 |
| 3 years | 3.19 | | 13.6 |
| 5 years | 3.19 | | 13.6 |
| 10 years | 3.19 | | 13.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 16/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 22/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 27/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 16/06/2017 | |
| Director/Board Member | 54 | 15/09/1999 | |
| Director/Board Member | 58 | 16/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.45% | -2.21% | - | - | 74Cr | |
| +3.90% | -0.39% | +376.72% | +599.59% | 3.96TCr | |
| -1.70% | +4.46% | +7.46% | +57.67% | 3.47TCr | |
| -2.01% | -0.76% | +26.35% | -6.83% | 3.44TCr | |
| +0.06% | +0.34% | +2.32% | +29.30% | 2.71TCr | |
| +0.46% | -3.49% | - | - | 1.62TCr | |
| -0.04% | -0.09% | +68.48% | +117.39% | 1.54TCr | |
| +1.12% | +1.91% | +15.90% | +19.65% | 1.41TCr | |
| 0.00% | +1.36% | +15.74% | -30.62% | 1.3TCr | |
| -0.08% | -3.01% | +1,271.69% | +649.69% | 1.18TCr | |
| Average | +0.13% | +0.04% | +223.08% | +179.48% | 2.29TCr | |
| Weighted average by Cap. | +0.24% | +0.36% | +171.43% | +187.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10Cr 11Cr 9.25Cr 8.52Cr 16Cr 1.1TCr 16Cr 110.51Cr 43Cr 540.76Cr 43Cr 42Cr 1.86TCr | 12Cr 14Cr 11Cr 11Cr 20Cr 1.37TCr 20Cr 136.82Cr 54Cr 669.48Cr 53Cr 52Cr 2.3TCr |
| Net income | 2.29Cr 2.62Cr 2.11Cr 1.95Cr 3.67Cr 252.11Cr 3.75Cr 25Cr 9.92Cr 123.47Cr 9.83Cr 9.62Cr 425.05Cr | 68L 77.81L 62.75L 57.84L 1.09Cr 75Cr 1.11Cr 7.5Cr 2.95Cr 37Cr 2.92Cr 2.86Cr 126.34Cr |
| Net Debt | -5.11Cr -5.85Cr -4.72Cr -4.35Cr -8.19Cr -563.3Cr -8.38Cr -56Cr -22Cr -275.88Cr -22Cr -21Cr -949.71Cr | -6.62Cr -7.57Cr -6.11Cr -5.63Cr -11Cr -729.21Cr -11Cr -73Cr -29Cr -357.14Cr -28Cr -28Cr -1.23TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/26/16 | €13.30 | -0.45% | 469 |
| 13/26/13 | €13.36 | -1.76% | 518 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
